Genmab: Darzalex sales in line with expectations

Cancer drug Darzalex, which Genmab developed and is now sold by Johnson & Johnson, had a fourth quarter revenue of USD 1.645bn, which is a tad over predictions.

Photo: Tuala Hjarnø / Genmab / PR

Sales of Genmab-developed bone marrow cancer drug Darzalex, which has been out-licensed to Johnson & Johnson, landed on the same level as was expected by analysts in the fourth quarter of 2021, the US-based pharmaceutical giant announces in a press release, which Genmab confirms in a statement.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs